SK279533B6 - Spôsob prípravy štandardizovaného vysoko čistého k - Google Patents

Spôsob prípravy štandardizovaného vysoko čistého k Download PDF

Info

Publication number
SK279533B6
SK279533B6 SK568-92A SK56892A SK279533B6 SK 279533 B6 SK279533 B6 SK 279533B6 SK 56892 A SK56892 A SK 56892A SK 279533 B6 SK279533 B6 SK 279533B6
Authority
SK
Slovakia
Prior art keywords
von willebrand
concentrate
vwf
willebrand factor
chromatography
Prior art date
Application number
SK568-92A
Other languages
English (en)
Slovak (sk)
Inventor
Miryana Burnouf-Radosevich
Thierry Burnouf
Original Assignee
Centre Regional De Transfusion Sanguine De Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Regional De Transfusion Sanguine De Lille filed Critical Centre Regional De Transfusion Sanguine De Lille
Publication of SK279533B6 publication Critical patent/SK279533B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK568-92A 1991-03-08 1992-02-26 Spôsob prípravy štandardizovaného vysoko čistého k SK279533B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9102804A FR2673632A1 (fr) 1991-03-08 1991-03-08 Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.

Publications (1)

Publication Number Publication Date
SK279533B6 true SK279533B6 (sk) 1998-12-02

Family

ID=9410505

Family Applications (1)

Application Number Title Priority Date Filing Date
SK568-92A SK279533B6 (sk) 1991-03-08 1992-02-26 Spôsob prípravy štandardizovaného vysoko čistého k

Country Status (29)

Country Link
US (1) US5408039A (xx)
EP (1) EP0503991B1 (xx)
JP (1) JP3435668B2 (xx)
AT (1) AT407115B (xx)
AU (1) AU645172B2 (xx)
BE (1) BE1004178A3 (xx)
BR (1) BR9200770A (xx)
CA (1) CA2062340C (xx)
CZ (1) CZ283633B6 (xx)
DE (2) DE122009000034I2 (xx)
DK (1) DK0503991T3 (xx)
EE (1) EE03057B1 (xx)
EG (1) EG20300A (xx)
ES (1) ES2121830T3 (xx)
FI (1) FI106721B (xx)
FR (1) FR2673632A1 (xx)
HU (1) HU215098B (xx)
IL (1) IL101043A (xx)
IT (1) IT1256692B (xx)
LT (1) LT3175B (xx)
NL (1) NL300394I1 (xx)
NO (1) NO301278B1 (xx)
NZ (1) NZ241701A (xx)
PL (1) PL168353B1 (xx)
RU (1) RU2088590C1 (xx)
SA (1) SA92120446B1 (xx)
SK (1) SK279533B6 (xx)
UA (1) UA27732C2 (xx)
ZA (1) ZA921430B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
DE19616540A1 (de) * 1995-11-10 1997-05-15 Immuno Ag Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT404358B (de) 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
RU2244556C2 (ru) 1999-02-22 2005-01-20 Юниверсити Оф Коннектикут Новые не содержащие альбумин составы фактора viii
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
FR2874216B1 (fr) 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
DE102004044419B4 (de) 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
DE102004044429B4 (de) * 2004-09-14 2009-04-30 Biotest Ag Verfahren zur Herstellung einer Zusammensetzung enthaltend von Willebrand Faktor
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
CA2690218C (en) 2007-06-13 2017-02-28 Csl Behring Gmbh Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
EP2073015A1 (en) 2007-12-21 2009-06-24 CSL Behring GmbH Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function
US20100273206A1 (en) * 2007-12-21 2010-10-28 Manfred Rauh Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function
KR101507718B1 (ko) 2008-06-24 2015-04-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｖｉｉｉ因子製剤
IT1396528B1 (it) 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
KR20120061898A (ko) 2009-08-20 2012-06-13 체에스엘 베링 게엠베하 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자
US9488625B2 (en) 2010-12-15 2016-11-08 Baxalta GmbH Purification of factor VIII using a conductivity gradient
AU2012318303B2 (en) 2011-10-18 2015-09-03 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII
KR20140083036A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
WO2015066769A1 (en) * 2013-11-08 2015-05-14 Csl Ltd. New method to concentrate von willebrand factor or complexes thereof
CA2953593C (en) 2014-07-02 2023-09-26 Csl Limited Modified von willebrand factor
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
WO2017066683A1 (en) * 2015-10-15 2017-04-20 Plasma Technologies, Llc Methods for extracting proteins from blood plasma
JP6851381B6 (ja) 2016-01-07 2021-04-21 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 変異切断型フォンウィルブランド因子
CN108779165B (zh) 2016-01-07 2022-12-02 康诺贝林伦瑙有限公司 突变的冯·维勒布兰德因子
CN105622746A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种从冷沉淀提取凝血因子ⅷ的废料中提取人血管性血友病因子的制备工艺
CN105541997A (zh) * 2016-02-04 2016-05-04 江西博雅生物制药股份有限公司 一种高纯度和高活性血管性血友病因子的制备工艺
CN105622747A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种vWF活性保护液
EP3488858A1 (en) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies A von willebrand factor composition for use in treating a pathology mediated by angiogenesis
CN114249812B (zh) * 2020-09-22 2023-09-15 四川远大蜀阳药业有限责任公司 一种降低vWF制品中IgM含量的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61166542A (ja) * 1985-01-18 1986-07-28 Hitachi Chem Co Ltd 感光性組成物
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5006642A (en) * 1987-06-29 1991-04-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Purification of von Willebrand Factor by affinity chromatography
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus

Also Published As

Publication number Publication date
NO920867D0 (no) 1992-03-05
ATA43692A (de) 2000-05-15
FI106721B (fi) 2001-03-30
PL168353B1 (pl) 1996-02-29
DE69227055T2 (de) 1999-04-22
AU1113192A (en) 1992-09-10
ITTO920189A1 (it) 1993-09-06
EE03057B1 (et) 1997-12-15
US5408039A (en) 1995-04-18
EP0503991B1 (fr) 1998-09-23
ITTO920189A0 (it) 1992-03-06
IT1256692B (it) 1995-12-12
RU2088590C1 (ru) 1997-08-27
DK0503991T3 (da) 1999-06-14
HU215098B (hu) 1998-09-28
DE122009000034I1 (de) 2010-04-08
CA2062340C (fr) 2000-05-09
AU645172B2 (en) 1994-01-06
LT3175B (en) 1995-02-27
IL101043A0 (en) 1992-11-15
FR2673632B1 (xx) 1995-05-05
FI920992A0 (fi) 1992-03-06
NO301278B1 (no) 1997-10-06
EG20300A (fr) 1998-10-31
UA27732C2 (uk) 2000-10-16
HUT63176A (en) 1993-07-28
IL101043A (en) 1997-02-18
AT407115B (de) 2000-12-27
EP0503991A1 (fr) 1992-09-16
FR2673632A1 (fr) 1992-09-11
CS56892A3 (en) 1992-09-16
CA2062340A1 (fr) 1992-09-09
NZ241701A (en) 1994-10-26
LTIP266A (en) 1994-07-15
ZA921430B (en) 1992-11-25
DE69227055D1 (de) 1998-10-29
PL293738A1 (en) 1992-09-21
DE122009000034I2 (de) 2011-06-16
HU9200767D0 (en) 1992-05-28
BE1004178A3 (fr) 1992-10-06
JPH0597696A (ja) 1993-04-20
NO920867L (no) 1992-09-09
NL300394I1 (nl) 2009-09-01
JP3435668B2 (ja) 2003-08-11
SA92120446B1 (ar) 2004-05-04
ES2121830T3 (es) 1998-12-16
FI920992A (fi) 1992-09-09
BR9200770A (pt) 1992-11-17
CZ283633B6 (cs) 1998-05-13

Similar Documents

Publication Publication Date Title
SK279533B6 (sk) Spôsob prípravy štandardizovaného vysoko čistého k
US5880265A (en) Method for isolation of highly pure von willebrand factor
DK175322B1 (da) Fremgangsmåde til separation af Faktor VIII, fibrinogen, fibronectin og von Willebrands faktor af humane eller animalske plasma og Faktor VIII opnået ved fremgangsmåden
US5872099A (en) High molecular and low molecular fractions of von Willebrand Factor
AU2003244850B2 (en) Processes for the preparation of fibrinogen
NO324659B1 (no) Utvinning av von Willebrand-faktor ved kationebytterkromatografi samt preparat inneholdende slik faktor og anvendelse derav.
DK162233B (da) Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US7888476B2 (en) Process for the preparation of a von Willebrand (FvW) factor concentrate by chromatography and a FvW concentrate thus obtainable
CA2749902C (en) New process for highly selective purification of two plasma proteins: von willebrand factor (vwf) and fibronectin (fn)
de Lille Burnouf-Radosevich et a1.
LV10193B (en) Highly clean and therapeutically usable standardized method for producing Willebrand factor concentrate for industrial production

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20100226